Literature DB >> 12009011

Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.

Akiko Iida-Klein1, Hua Zhou, Shi Shou Lu, Lance R Levine, Mercedes Ducayen-Knowles, David W Dempster, Jeri Nieves, Robert Lindsay.   

Abstract

The cellular and molecular events triggering the anabolic response of the skeleton to exogenous parathyroid hormone (PTH) are not well understood. Despite the numerous bone mass studies in rats, few data are available for mice. Therefore, we treated 10-week-old female intact C57BL/6J mice with human PTH(1-34) delivered subcutaneously at a dose of 40 microg/kg per day 5 days a week for 3 weeks and 7 weeks. Bone mineral density (BMD) of total bone, femur, tibia, and lumbar vertebrae was measured weekly by PIXImus. Bone turnover was examined by histomorphometry, and gene expression of bone formation and resorption markers and osteoclastogenesis regulators in the excised femur and tibia was assessed by reverse-transcription polymerase chain reaction (RT-PCR) at 3 weeks and 7 weeks. The PTH-stimulated increase in BMD was more prominent in the tibia and femur than in the lumbar vertebrae, with an anabolic effect detected within 1-2 weeks and BMD continuing to increase. The appearance of a detectable PTH-stimulated increase in BMD was slower in the lumbar vertebrae where the increase was only significant after 7 weeks of treatment. Histomorphometric analysis of the proximal tibia at both 3 weeks and 7 weeks indicated significant time-dependent increases in trabecular area, trabecular number, trabecular and cortical widths, and osteoblast and osteoid perimeters. In the lumbar vertebrae, these stimulatory effects of PTH on trabecular area, trabecular number, and cortical width were smaller and not detected until 7 weeks. PTH-stimulated increases in bone turnover were evident by increased gene expression of osteocalcin (OC), tartrate-resistant acid phosphatase (TRAP), and receptor of activator nuclear factor kappaB (NF-kappaB) ligand (RANKL) in the tibia and femur. No significant difference in gene expression was observed between the two long bone sites. In conclusion, PTH exerts an anabolic action at the tissue and cellular levels in intact mice and the magnitude and temporal pattern of this anabolic action, as assessed by densitometry and histomorphometry, are skeletal site specific.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009011     DOI: 10.1359/jbmr.2002.17.5.808

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  58 in total

1.  Production, characterisation, and cytocompatibility of porous titanium-based particulate scaffolds.

Authors:  B J C Luthringer; F Ali; H Akaichi; F Feyerabend; T Ebel; R Willumeit
Journal:  J Mater Sci Mater Med       Date:  2013-06-27       Impact factor: 3.896

2.  Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.

Authors:  Yu Shao; Selene Hernandez-Buquer; Paul Childress; Keith R Stayrook; Marta B Alvarez; Hannah Davis; Lilian I Plotkin; Yongzheng He; Keith W Condon; David B Burr; Stuart J Warden; Alexander G Robling; Feng-Chun Yang; Ronald C Wek; Matthew R Allen; Joseph P Bidwell
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

3.  Overexpression of the transcriptional factor Runx2 in osteoblasts abolishes the anabolic effect of parathyroid hormone in vivo.

Authors:  Didier Merciris; Caroline Marty; Corinne Collet; Marie-Christine de Vernejoul; Valerie Geoffroy
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

4.  Anabolic effect of intermittent PTH(1-34) on the local microenvironment during the late phase of periodontal repair in a rat model of tooth root resorption.

Authors:  S Lossdörfer; F Yildiz; W Götz; Y Kheralla; A Jäger
Journal:  Clin Oral Investig       Date:  2009-03-12       Impact factor: 3.573

5.  Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation.

Authors:  Makoto Okazaki; Sebastien Ferrandon; Jean-Pierre Vilardaga; Mary L Bouxsein; John T Potts; Thomas J Gardella
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-22       Impact factor: 11.205

6.  Intermittent administration of parathyroid hormone ameliorates periapical lesions in mice.

Authors:  Masato Otawa; Ryuichiro Tanoue; Hirofumi Kido; Yoshihiko Sawa; Junro Yamashita
Journal:  J Endod       Date:  2015-01-30       Impact factor: 4.171

7.  CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.

Authors:  Fei Liu; Sun-Kyeong Lee; Douglas J Adams; Gloria A Gronowicz; Barbara E Kream
Journal:  Bone       Date:  2007-02-01       Impact factor: 4.398

8.  Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts.

Authors:  Estelle N Bianchi; Serge L Ferrari
Journal:  Bone       Date:  2009-06-25       Impact factor: 4.398

9.  The PTH-Gαs-protein kinase A cascade controls αNAC localization to regulate bone mass.

Authors:  Martin Pellicelli; Julie A Miller; Alice Arabian; Claude Gauthier; Omar Akhouayri; Joy Y Wu; Henry M Kronenberg; René St-Arnaud
Journal:  Mol Cell Biol       Date:  2014-02-18       Impact factor: 4.272

10.  Nmp4/CIZ suppresses parathyroid hormone-induced increases in trabecular bone.

Authors:  Alexander G Robling; Paul Childress; Jun Yu; Jessica Cotte; Aaron Heller; Binu K Philip; Joseph P Bidwell
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.